Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumourigenic liver fluke Opisthorchis viverrini

Plieskatt, Jordan; Rinaldi, Gabriel; Feng, Yanjun; Peng, Jin; Yonglitthipagon, Ponlapat; Easley, Samantha; Laha, Therawach; Pairojkul, Chawalit; Bhudhisawasdi, Vajarabhongsa; Sripa, Banchob; Brindley, Paul J.; Mulvenna, Jason; Bethony, Jeffrey M.

doi:10.1016/j.jhep.2014.05.035

Cited by 39 publications

(48 citation statements)

References 34 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aberrant expression of 5 miRNAs reported in this study (miRNA-3615, miRNA-342, miRNA-339, miRNA-182, and miRNA-4485) has been previously reported in relation to liver cirrhosis or HCC malignancy (29) as well as some other cancers such as lung adenocarcinoma (30) , melanoma (31) , colorectal cancer (32) (33) , gastric cancer (34) (35) , intrahepatic cholangiocarcinoma (36) , colon cancer (37) , and breast cancer (38) (39) . Recently Wojcicka et al employed next generation sequencing to investigate the expression of microRNA in tissue samples of HBV/HCV infected with liver cirrhosis and HCC.…”

Section: Discussionsupporting

confidence: 75%

Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B

Riazalhosseini

Mohamed

Apalasamy

et al. 2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Hepatitis B virus (HBV) constitutes an important risk factor for cirrhosis and hepatocellular carcinoma (HCC). The link between circulating microRNAs and HBV has been previously reported, although not as a marker of liver disease progression in chronic hepatitis B (CHB). The aim of this study was to characterize miRNA expression profiles between CHB with and without cirrhosis or HCC. Methods: A total of 12 subjects were recruited in this study. We employed an Affymetrix Gene Chip miRNA 3.0 Array to provide universal miRNA coverage. We compared microRNA expression profiles between CHB with and without cirrhosis/HCC to discover possible prognostic markers associated with the progression of CHB. Results: Our results indicated 8 differently expressed microRNAs, of which miRNA-935, miRNA-342, miRNA-339, miRNA-4508, miRNA-3615, and miRNA-3200 were up-regulated, whereas miRNA-182 and miRNA-4485 were down-regulated in patients with CHB who progressed to cirrhosis/HCC as compared to those without progression. Conclusions: We demonstrated the differential expression of between patients with HBV without cirrhosis/HCC and those who had progressed to these more severe conditions. These miRNAs may serve as novel and non-invasive prognostic markers for early detection of CHB-infected patients who are at risk of progression to cirrhosis and/or HCC.

show abstract

Section: Discussionsupporting

confidence: 75%

Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B

Riazalhosseini

Mohamed

Apalasamy

et al. 2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…Aberrant expression of miRNAs often occurs in CCA and plays critical roles in its progression [32]. Thus, it is critical to uncover the function of miRNAs in CCA and their mechanisms.…”

Section: Discussionmentioning

confidence: 99%

miR-191 Inhibition Induces Apoptosis Through Reactivating Secreted Frizzled-Related Protein-1 in Cholangiocarcinoma

Kang

Leng

Liu

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Cholangiocarcinoma (CCA) is one of the most common malignant tumors of the biliary tract originating from biliary epithelial cells. Although many therapeutic strategies have been developed to treat CCA, the survival rate for CCA patients is still quite low. Thus it is urgent to elucidate the pathogenesis of CCA and to explore novel therapeutic targets. miR-191 has been shown to be associated with many human solid cancers, but the function of miR-191 in CCA is still poorly understood. Methods: We first investigated the expression level of miR-191 in human CCA tissues and cell lines with quantitative real-time PCR (qRT-PCR). The effects of miR-191 on CCA cells were determined by Cell Counting Kit-8 assay, colony formation assay and acridine orange/ethidium bromide staining. Finally, we utilized qRT-PCR, western blot and luciferase reporter assays to verify the miR-191 target gene. Results: We showed that miR-191 was up-regulated in CCA cell lines and patients. Knockdown of miR-191 by transfection of its inhibitor sequence blocked RBE cells viability and induced apoptosis of RBE cells. Both qRT-PCR and western blot analysis showed that the secreted frizzled-related protein-1 (sFRP1) level was negatively correlated with that of miR-191. Luciferase assay validated that sFRP1 was a direct target of miR-191. Moreover, knockdown of miR-191 led to suppression of Wnt/β-catenin signaling activation. Co-transfection of sFRP1 small interfering RNA (siRNA) and miR-191 inhibitor re-activated the Wnt/β-catenin signaling pathway as detected by an increased level of β-catenin and phosphorylation of GSK-3β, and restored the expression of survivin and c-myc in RBE cells. Co-transfection of sFRP1 siRNA with miR-191 inhibitor restored the colony formation ability and viability of RBE cells. Conclusion: Taken together, our results demonstrate a novel insight into miR-191 biological function in CCA. Our findings suggest that miR-191 is a potential therapeutic target of CCA treatment.

show abstract

“…The arrays included 94 miRNA (mature, human) primers that provide potential signatures for cholangiocarcinoma [20]. We used 12 U Bacteroides heparinase I during RT and compared this with no-treatment of RNA.…”

Section: Resultsmentioning

confidence: 99%

Circumventing qPCR inhibition to amplify miRNAs in plasma

et al. 2014

Self Cite

View full text Add to dashboard Cite

BackgroundCirculating microRNAs (c-miRNAs) have be identified in saliva, urine and blood, which has led to increasing interest in their development as biomarkers for diverse diseases including cancers. One of the key advantages of c-miRNAs over other biomarkers is the ability to be amplified and quantified by quantitative PCR (qPCR). However, at phlebotomy when whole blood is dispensed into heparinized tubes, residual levels of the anti-coagulant lithium heparin may remain in the plasma and hence with RNA isolated from the plasma. This can confound the detection of c-miRNAs by qPCR because it inhibits reverse transcriptase (RT). Here we present a procedure, modified from earlier techniques, to detect c-miRNAs in plasma that improves sensitivity and streamlines performance.FindingsTreatment of total RNA isolated from human blood plasma with Bacteroides heparinase I during reverse transcription at 37°C for one hour improved sensitivity and performance of the qPCR. This is in comparison to no treatment or treatment of the RNA prior to RT, which is the current suggested method and exposes plasma to Flavobacterium heparinum heparinase I for up to 2 hours before RT. This modest alteration improved qPCR performance and resulted in lowered threshold cycles (Ct) for detection of the target sequence, candidate c-miRNA biomarkers, and controls. It also reduced the expense and number of processing steps, shortening the duration of the assay and minimizing exposure of RNA to elevated temperatures.ConclusionIncorporating Bacteroides heparinase I treatment into conventional RT protocols targeting c-miRNA in plasma can be expected to expedite the discovery of biomarkers.

show abstract

Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumourigenic liver fluke Opisthorchis viverrini

Cited by 39 publications

References 34 publications

Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B

Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B

miR-191 Inhibition Induces Apoptosis Through Reactivating Secreted Frizzled-Related Protein-1 in Cholangiocarcinoma

Circumventing qPCR inhibition to amplify miRNAs in plasma

Contact Info

Product

Resources

About